Inhalable Excipient-Free Dry Powder of Tigecycline for the Treatment of Pulmonary Infections.
Excipient Free
Jet Milling
Lung Infections
Pulmonary Delivery
Tigecycline
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
04 09 2023
04 09 2023
Historique:
medline:
5
9
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
ppublish
Résumé
Tigecycline (TIG) is a broad-spectrum antibiotic that has been approved for the treatment of a number of complicated infections, including community-acquired bacterial pneumonia. Currently it is available only as an intravenous injection that undergoes rapid chemical degradation and limits the use to in-patient scenarios. The use of TIG as an inhaled dry powder inhaler may offer a promising treatment option for patients with multidrug-resistant respiratory tract infections, such as
Identifiants
pubmed: 37606919
doi: 10.1021/acs.molpharmaceut.3c00395
doi:
Substances chimiques
Tigecycline
70JE2N95KR
Powders
0
Anti-Bacterial Agents
0
Excipients
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM